Results 31 to 40 of about 17,446,860 (311)
Pediatric Blood &Cancer, EarlyView.ABSTRACT Objective To evaluate selumetinib exposure using therapeutic drug monitoring (TDM) in pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN), assess interpatient pharmacokinetic variability, and explore the relationship between drug exposure, clinical response, and adverse effects.
Janka Kovács +8 more
wiley +1 more source
Third year survival guide: 1997-1998 [PDF]
, 1997 Advice compiled by Boston University School of Medicine students for incoming first year students and third or fourth year students preparing for clinical ...
Boston University School of Medicine
core
, 2013 The 2013 Annual Report includes a review of the year, research highlights and activities across the School's three Faculties, and key facts and figures.
London School of Hygiene & Tropical Medicine
core
BMJ, 2008 This week’s journal captures modern medicine’s ambivalence about modern medicines. On one hand, we look to new drugs to deliver us from illness and disease. On the other, we view the companies who deliver them with suspicion or disdain. The journal has articles to buttress both viewpoints. Firstly, drugs as salvation.
openaire +2 more sources
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background and Aims Wilms tumour (WT) has excellent event‐free and overall survival (OS). However, small differences exist between countries participating in the same international study. This led us to examine variation in adherence to protocol recommendations as a potential contributing factor.
Suzanne Tugnait +23 more
wiley +1 more source
, 1988 Newsletter of the Evans Memorial Department of Clinical Research and Preventive Medicine at University ...
University Hospital, Evans Memorial Department of Clinical Research and Preventive Medicine
core
Pediatric Blood &Cancer, EarlyView.ABSTRACT Arteriovenous malformations (AVMs) are rare, high‐flow, vascular anomalies that can occur either sporadically or as part of a genetic syndrome. AVMs can progress with serious morbidity and even mortality if left unchecked. Sirolimus is an mTOR inhibitor that is effective in low‐flow vascular malformations; however, its role in AVMs is unclear.
Will Swansson +3 more
wiley +1 more source
Correction: Association between the 2012 Health and Social Care Act and specialist visits and hospitalisations in England: A controlled interrupted time series analysis. [PDF]
PLoS Medicine, 2018 [This corrects the article DOI: 10.1371/journal.pmed.1002427.].
PLOS Medicine Staff
doaj +1 more source
, 1987 Newsletter of the Evans Memorial Department of Clinical Research and Preventive Medicine at University ...
Levinsky, Norman G. +1 more
core